Anticancer Therapies – Products
Product News
FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer
On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Product News
Thermo Fisher Scientific Introduces Animal Origin-Free Formulation To Support Scaling of Cell Therapy Manufacturing
Breakthrough medium delivers speed and scale to CAR-T cell therapy manufacturers.
Product News
University of Liverpool To Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical
The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.
Product News
Therapeutic Potential of CD20 X CD3 Bispecific Antibodies
As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Compendium
Cancer Immunotherapies: The Paths From Models to Treatments
In this compendium, Technology Networks presents a collection of handpicked resources, including infographics, listicles, an article and webinar, that will help you to learn more about the latest advancements with disease modeling and cancer immunotherapies.
Product News
N4 Pharma’s Novel Delivery Systems, Nuvec® and LipTide®, Advance Towards Commercialisation
N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.
Whitepaper
Advances in Cell Therapy
This article examines recent advancements in cell therapy research, from promising lab findings poised for clinical translation to enhancements in development, testing, and manufacturing processes.
Whitepaper
Improving Cancer Patient Care With Professor Mark Lawler
In this article, Mark Lawler, professor of digital health, answers your questions about these revolutionary techniques and discusses the barriers to their implementation in the clinic. Prof. Lawler has an international reputation in cancer research and a focus on developing a molecular understanding of cancer to improve patient care, including through precision medicine.
Whitepaper
Advanced Oncology Treatment Candidates Developed With Next-Generation Preclinical Models
One factor that can significantly impact the success of oncology drug development is the preclinical model used. The right model can provide valuable insights into key interactions within the body and help researchers to better understand how tumors respond to treatment.
Whitepaper
Novel CAR Technology To Transform Cancer Therapy
Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.
Advertisement